Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 49Active not recruiting 29Completed 14Not yet recruiting 10Withdrawn 2Terminated 1Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Central Nervous System Neoplasms 1Borderline Resectable Pancreatic Adenocarcinoma 1

Interventions

pembrolizumab 4Radiotherapy 4Radiation 4ALT-803 4fludarabine 3Prednisone 3Etoposide 3Cytarabine 3Cyclophosphamide 3Cisplatin 3Biopsy 3sacituzumab govitecan 2daratumumab 2atezolizumab 2Vincristine 2Temozolomide 2Surveys and Questionnaires 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Irinotecan 2Gemcitabine 2Doxorubicin 2Blood Specimen Collection 2Bevacizumab 2Androgen Antagonists 2130-nm albumin-bound paclitaxel 2zimberelimab 1vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Irinotecan × 90 days × Clear all
NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡